초록 ▼

A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight

A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight loss drug.

대표청구항 ▼

1. A method of maintaining lean muscle mass during weight loss comprising: administering a weight loss therapy; andelectrically stimulating a splanchnic nerve of a mammal using a ramp-cycling stimulation therapy, wherein the mammal losses weight and substantially maintains lean muscle mass. 2. The m

1. A method of maintaining lean muscle mass during weight loss comprising: administering a weight loss therapy; andelectrically stimulating a splanchnic nerve of a mammal using a ramp-cycling stimulation therapy, wherein the mammal losses weight and substantially maintains lean muscle mass. 2. The method according to claim 1, wherein at least 5% of weight loss is attributable to loss in central fat. 3. The method according to claim 1, wherein the weight loss therapy is a pharmaceutical. 4. The method according to claim 3, wherein less than 50% a normally prescribed dosage of the pharmaceutical is administered. 5. The method according to claim 1, wherein a pharmaceutical is administered in parallel with the electrical stimulation. 6. The method according to claim 1, wherein a pharmaceutical is administered in series with the electrical stimulation. 7. A method of preventing or treating an eating disorder in a mammal comprising: electrically stimulating a splanchnic nerve of the mammal using a ramp-cycling stimulation therapy; andadministering a weight loss composition in a pharmaceutically effective amount to produce weight loss in the mammal. 8. The method of claim 7, wherein the weight loss composition comprises an appetite suppressant. 9. The method of claim 8, wherein the appetite suppressant is one or more selected from the group consisting of a noradrenergic agent, a serotonergic agent, and an adrenergic/serotonergic agent. 10. The method of claim 9, wherein the appetite suppressant is one or more selected from the group consisting of phenylpropanolamine, phentermine, fenfluramine, dexfenfluramine, fluoxetine, sibutramine. 11. The method of claim 7, wherein the weight loss composition comprises a thermogenic agent. 12. The method of claim 11, wherein the thermogenic agent is one or more selected from the group consisting of a sympathomimetic and a selective Beta 3-adrenergic agonist. 13. The method of claim 7, wherein the weight loss composition comprises a digestive inhibitor. 14. The method of claim 7, wherein the digestive inhibitor is a lipase inhibitor. 15. The method of claim 14, wherein the lipase inhibitor is tetrahydrolipostatin. 16. The method of claim 7, wherein the weight loss composition comprises a cannabinoid antagonist. 17. The method of claim 7, wherein the weight loss composition comprises an anatagonist of a hormone or hormone receptor that increases food intake. 18. The method of claim 17, wherein the hormone is one or more selected from the group consisting of Neuropeptide Y, Orexins, and Ghrelin. 19. The method of claim 7, wherein the weight loss composition comprises an agonist of a hormone or hormone receptor that decreases food intake. 20. The method of claim 19, wherein the hormone is one or more selected from the group consisting of Glucagon-like-peptide 1, Cholecystokinin, Peptide YY (3-36), amylin, and melanocortins. 21. The method of claim 7, wherein the weight loss composition comprises one or more selected from leptin, a leptin stimulator, adiponectin, and an adiponectin stimulator. 22. The method of claim 7, wherein the weight loss composition comprises one or more selected from the group consisting of at least one appetite suppressant, at least one digestive inhibitor, at least one cannabinoid antagonist, at least one anatagonist of a hormone or hormone receptor that increases body weight, and at least one agonist of a hormone or hormone receptor that decreases body weight. 23. The method of claim 7, further comprising performing a surgical procedure configured to produce weight loss in the mammal. 24. A method of treating or prevent an eating disorder comprising: electrically stimulating a splanchnic nerve of a mammal using a ramp-cycling stimulation therapy; andperforming a surgical procedure configured to produce weight loss in the mammal. 25. The method of claim 24, wherein the surgical procedure comprises a bypass. 26. The method of claim 25, wherein the surgical procedure comprises one or more selected the group consisting of jejuno-illeo bypass and a roux-en-Y gastric bypass. 27. The method of claim 24, wherein the surgical procedure comprises a gastric restrictive procedure. 28. The method of claim 24, wherein the gastric restrictive procedure comprises one or more selected from the group consisting of gastric banding, adjustable gastric banding, gastric stapling, and vertical banded gastroplasty. 29. The method of claim 24, wherein the surgical procedure comprises a partial biliopancreatic diversion. 30. The method of claim 24, wherein the surgical procedure comprises implanting a gastric displacement device. 31. The method of claim 24, wherein the gastric displacement device is a gastric balloon. 32. A method of preventing or treating an eating disorder comprising: electrically stimulating a splanchnic nerve in a mammal to reduce a level of serum C-Reactive Protein (CRP) in the mammal using a ramp-cycling stimulation therapy; andrepeating splanchnic nerve stimulation in a manner to maintain a reduced level of CRP. 33. A method of preventing or treating an eating disorder comprising: electrically stimulating a splanchnic nerve in a mammal to reduce a level of serum C-Reactive Protein (CRP) in the mammal; andadministering a weight loss drug in a dose configured to produce weight loss in the mammal. 34. The method of claim 33, wherein the step of administering a weight loss drug comprises administering exogenous leptin to the mammal. 35. The method of claim 33, wherein the administering of the weight loss drug is configured to maintain a reduced level of serum C-Reactive Protein (CRP).